Abstract

EARLY AGGRESSIVE TREATMENT: METFORMIN-VOGLIBOSE COMBINATION THERAPY VS METFORMIN MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENT.

Dillu R.D.*, Singh H., Bhardwaj B.L. and Singh K.D.

Abstract

Diabetes has rapidly gained the status of being a pandemic. Adequate treatment of diabetes mellitus is very challenging. Numbers of drugs, with different mechanism of action, catering the needs of diverse patient profile are being marketed. Nowadays early aggressive treatment with combination therapy is advocated for achieving tight glycemic controls, keeping a check on hypoglycaemia. Therefore present study was designed to compare effectiveness of metforminvoglibose combination regime with metformin monotherapy in newly diagnosed T2DM. Method- The present study was designed as open, parallel and randomized comparison of effectiveness of metforminvoglibose with metformin alone over a period of 24 weeks in newly diagnosed T2DM patients attending Internal medicine OPD, Rajindra Hospital Patiala. 80 patients were randomly allocated into two treatment group after verifying for inclusion and exclusion criteria and obtaining written informed consent. Maximum dose of metformin given was 2.5 g/d and that of voglibose was 0.9mg/d.FBS and PPBS were done at baseline 4th week, 12th week and 24th week. HbA1C was monitored at baseline 12th week and 24th week. Results- At the end of 24 weeks metformin monotherapy reduce HbA1C by 1.56±0.59%, FBS by 34.12±16.70 mg/dL and PPBS was reduced by 78.37±32.2 mg/dL. Combination therapy reduced HbA1C by 1.73±0.56, FBS by 41.60±27.38 mg/dL and PPBS was reduced by 94.22±19.80 mg/dL. Conclusion- Combination therapy showed greater reduction in PPBS as compared to Metformin monotherapy.

Keywords: Diabetes mellitus, Voglibose, Metformin, Postprandial hyperglycaemia, early aggressive treatment.